Health testing with all subjects who participated in any phase I clinical study and received at least one dose of HTL0018318/AGN-242071 to date.

Health testing with all subjects who participated in any phase I clinical study and received at least one dose of HTL0018318/AGN-242071 to date. - HTL0018318/AGN-242071 Health Testing Programme

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48060

Enrollment

170

Registered

2019-05-21

Start date

2019-06-25

Completion date

Unknown

Last updated

2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Health

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All subjects who received at least one dose of active study medication in any prior HTL0018318/AGN-242071 clinical study.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Liver Ultrasound Clinical Laboratory Assessments Optional genetics & biomarkers	—

Secondary

Measure	Time frame
N.A.	—

Countries

Netherlands

Outcome results